Effect of chitosan chewing gum on reducing serum phosphorus in hemodialysis patients: A multi-center, randomized, double-blind, placebo-controlled trial

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Akizawa, Tadao ^a   Tsuruta, Yoshinari ^b   Okada, Yoichi ^c   Miyauchi, Yoshihiro ^d   Suda, Akio ^e   Kasahara, Hiroshi ^f   Sasaki, Nobuhiro ^g   Maeda, Yoshitaka ^h   Suzuki, Takako ⁱ   Matsui, Noriaki ^j   Niwayama, Jun ^k   Suzuki, Toshiaki ^l   Hara, Hideaki ^m   Asano, Yasushi ^g   Komemushi, Sadao ⁿ   Fukagawa, Masafumi ^o  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Meiyo Clinic   (Japan)

^c Maruko General Hospital   (Japan)

^d ASAHI GENERAL HOSPITAL   (Japan)

^e SUDA Clinic   (Japan)

^f Suwa Red Cross Hospital   (Japan)

^g Japanese Red Cross Koga Hospital   (Japan)

^h JA Toride Medical Center   (Japan)

ⁱ Komagome Kyouritsu Clinic   (Japan)

^j TSUCHIURA KYODO GENERAL HOSPITAL   (Japan)

^k Sumiyoshi Clinic Hospital   (Japan)

^l Asagaya Suzuki Clinic   (Japan)

^m GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

ⁿ Osaka Prefecture University   (Japan)

^o TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Chewing gum; Chitosan; Clinical trial; Hemodialysis; Hyperphosphatemia; Phosphorus binders

Indexed keywords

CALCIUM CARBONATE; CHITOSAN; FIBROBLAST GROWTH FACTOR 23; HS 219; PARATHYROID HORMONE; PHOSPHATE BINDING AGENT; PHOSPHORUS; PLACEBO; SEVELAMER; UNCLASSIFIED DRUG; CHEWING GUM; DELAYED RELEASE FORMULATION;

ADD ON THERAPY; ARTICLE; CALCIUM BLOOD LEVEL; CHEWING GUM; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; MAJOR CLINICAL STUDY; MALE; MASTICATION; MULTICENTER STUDY; PARALLEL DESIGN; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SALIVA LEVEL; TOOTH FILLING; UNSPECIFIED SIDE EFFECT; ADMINISTRATION AND DOSAGE; ADULT; AGED; BLOOD; CLINICAL TRIAL; COMPLICATION; DELAYED RELEASE FORMULATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PLACEBO EFFECT; RENAL REPLACEMENT THERAPY; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; CHEWING GUM; CHITOSAN; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHORUS; PLACEBO EFFECT; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84902920199     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-98     Document Type: Article

References (31)

1. An overview of regular dialysis treatment in Japan (as of 31 December 2010). Nakai S, Watanabe Y, Masakane I, Wada A, Shoji T, Hasegawa T, Nakamoto H, Yamagata K, Kazama JJ, Fujii N, Itami N, Shinoda T, Shigematsu T, Marubayashi S, Morita O, Hashimoto S, Suzuki K, Kimata N, Hanafusa N, Wakai K, Hamano T, Ogata S, Tsuchida K, Taniguchi M, Nishi H, Iseki K, Tsubakihara Y, Ther Apher Dial 2012 16 483 521 10.1111/j.1744-9987.2012.01143.x 23190510
2. Dietary phosphorus, serum phosphorus, and cardiovascular disease. Menon MC, Ix JH, Ann N Y Acad Sci 2013 1301 21 26 10.1111/nyas.12283 24117725
3. Control of hyperphosphatemia among patients with ESRD. Coladonato JA, J Am Soc Nephrol 2005 16 107 S114 10.1681/ASN.2005060663 16251245
4. Oral phosphate binders in patients with kidney failure. Tonelli M, Pannu N, Manns B, N Engl J Med 2010 362 1312 1324 10.1056/NEJMra0912522 20375408
5. The safety of phosphate binders. Almirall J, Valenzuela MP, Expert Opin Drug Saf 2006 5 675 686 10.1517/14740338.5.5.675 16907657
6. Salivary phosphate secretion in chronic kidney disease. Savica V, Calò L, Santoro D, Monardo P, Granata A, Bellinghieri G, J Ren Nutr 2008 18 87 90 10.1053/j.jrn.2007.10.018 18089451
7. Phosphate salivary secretion in hemodialysis patients: implications for the treatment of hyperphosphatemia. Savica V, Calò LA, Caldarera R, Cavaleri A, Granata A, Santoro D, Savica R, Muraca U, Mallamace A, Bellinghieri G, Nephron Physiol 2007 105 52 55 10.1159/000098544
8. Decreased salivary function in patients with end-stage renal disease requiring hemodialysis. Kao CH, Hsieh JF, Tsai SC, Ho YJ, Chang HR, Am J Kidney Dis 2000 36 1110 1114 10.1053/ajkd.2000.19810 11096033
9. Decreased salivary flow rate as a dipsogenic factor in hemodialysis patients: evidence from an observational study and a pilocarpine clinical trial. Sung JM, Kuo SC, Guo HR, Chuang SF, Lee SY, Huang JJ, J Am Soc Nephrol 2005 16 3418 3429 10.1681/ASN.2005040346 16177001
10. Measuring salivary flow: Challenges and opportunities. Mahvash NM, Kumar SKS, J Am Dent Assoc 2008 139 35S 40S 10.14219/jada.archive.2008.0353 18460678
11. A meta-analysis evaluating the impact of chitosan on serum lipids in hypercholesterolemia patients. Baker WL, Tercius A, Anglade M, White CM, Coleman CI, Ann Nutr Metab 2009 55 368 374 10.1159/000258633 19923803
12. Evaluating efficacy of a chitosan product using a double-blinded, placebo-controlled protocol. Kaats GR, Michalek JE, Preuss HG, J Am Coll Nutr 2006 25 389 394 10.1080/07315724.2006.10719550 17031007
13. Potential applications for alternative medicine to treat obesity in an aging population. Cherniack EP, Altern Med Rev 2008 13 34 42 18377101
14. Production of oligosaccharides as promising new food additive generation. Barreteau H, Delattre C, Michaud P, Food Technol Biotechnol 2006 44 323 333
15. Salivary phosphate-binding chewing gum reduces hyperphosphatemia in dialysis patients. Savica V, Calò LA, Monad P, Davis PA, Granata A, Santoro D, Savica R, Musolino R, Comelli MC, Bellinghieri G, J Am Soc Nephrol 2009 20 639 644 10.1681/ASN.2008020130 19020004
16. A quantitative test for xerostomia. The Saxon test, an oral equivalent of the Schirmer test. Kohler PF, Winter ME, Arthritis Rheum 1985 28 1128 1132 10.1002/art.1780281008 4052124
17. R: A language and environment for statistical computing. R Development Core Team, R Foundation for Statistical Computing Vienna, Austria 2009 URL http://www.R-project.org
18. Synthesis of phosphorylated chitosan by novel method and its characterization. Jayakumar R, Nagahama H, Furuike T, Tamura H, Int J Biol Macromol 2008 42 335 339 10.1016/j.ijbiomac.2007.12.011 18279950
19. Effect of chitosan on renal function in patients with chronic renal failure. Jing SB, Li L, Ji D, Takiguchi Y, Yamaguchi T, J Pharm Pharmacol 1997 49 721 723 10.1111/j.2042-7158.1997.tb06099.x 9255718
20. Comparison of three salivary flow rate assessment methods in an elderly population. Jones JM, Watkins CA, Hand JS, Warren JJ, Cowen HJ, Community Dent Oral Epidemiol 2000 28 177 184 10.1034/j.1600-0528.2000.280303.x 10830644
21. Measuring salivary flow: challenges and opportunities. Navazesh M, Kumar SK, J Am Dent Assoc 2008 139 Suppl 35S 40S 18460678
22. Acute effects of hemodialysis on salivary flow rate and composition. Bots CP, Brand HS, Veerman EC, Valentijn-Benz M, Henskens YM, Valentijn RM, Vos PF, Bijlsma JA, Ter Wee PM, Van Amerongen BM, Nieuw Amerongen AV, Clin Nephrol 2007 67 25 31 10.5414/CNP67025 17269596
23. Oral manifestations and salivary flow rate, pH, and buffer capacity in patients with end-stage renal disease undergoing hemodialysis. Kho HS, Lee SW, Chung SC, Kim YK, Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999 88 316 319 10.1016/S1079-2104(99)70035-1 10503861
24. Salivary flow patterns and the health of hard and soft oral tissues. Dawes C, J Am Dent Assoc 2008 139 Suppl 18S 24S 18460676
25. Chewing gum and a saliva substitute alleviate thirst and xerostomia in patients on haemodialysis. Bots CP, Brand HS, Veerman EC, Korevaar JC, Valentijn-Benz M, Bezemer PD, Valentijn RM, Vos PF, Bijlsma JA, ter Wee PM, Van Amerongen BM, Nieuw Amerongen AV, Nephrol Dial Transplant 2005 20 578 584 10.1093/ndt/gfh675 15665029
26. Changes in salivary composition in patients with renal failure. Tomás I, Marinho JS, Limeres J, Santos MJ, Araújo L, Diz P, Arch Oral Biol 2008 53 528 532 10.1016/j.archoralbio.2008.01.006 18294611
27. Evaluation of salivary parameters and dental status in adult hemodialysis patients. Bayraktar G, Kazancioglu R, Bozfakioglu S, Yildiz A, Ark E, Clin Nephrol 2004 62 380 383 10.5414/CNP62380 15571184
28. Effect of Salivary Phosphate-Binding Chewing Gum on Serum Phosphate in Chronic Kidney Disease. Block GA, Persky MS, Shamblin BM, Baltazar MF, Singh B, Sharma A, Pergola P, Smits G, Comelli MC, Nephron Clin Pract 2013 123 93
29. What Can We Learn from the Saga of Chitosan Gums in Hyperphosphatemia Therapy? Oh MS, Uribarri J, Clin J Am Soc Nephrol 2014 9 967 970 10.2215/CJN.09230913 24408115
30. FGF23: a key player in mineral and bone disorder in CKD. Komaba H, Fukagawa M, Nefrologia 2009 29 392 396 19820750
31. FGF-23 in patients with end-stage renal disease on hemodialysis. Nakatsuka K, Nagasue K, Okuno S, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y, Kidney Int 2004 65 1943 1946 10.1111/j.1523-1755.2004.00604.x 15086938